GleamWall
中文EN

IRLA IRulya Therapeutics Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1662774 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-87.4%
TTM EPS YoY193.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-98.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets26.6%
Debt / equity—
Current ratio14.72x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.44x
Accruals ratio-55.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$35.38M$18.59M
SG&A expense$15.05M$17.58M
Operating income-$58.07M-$57.28M
Pretax income-$80.77M-$56.74M
Income tax$3.21M$87,000
Net income-$83.98M-$56.83M
EBITDA-$57.93M-$57.10M
EPS (basic)-1.68-1.31
EPS (diluted)-1.68-1.31
Weighted avg. shares (diluted)50.10M43.26M
Balance sheet
Cash & equivalents$5.81M$6.21M
Short-term investments$11.94M$34.57M
Current assets$22.90M$44.04M
PP&E, net$595,000$315,000
Goodwill—$0
Intangibles$67.82M$60.05M
Total assets$93.52M$114.48M
Current liabilities$43.23M$7.28M
Short-term debt$18.03M$0
Long-term debt$0$14.32M
Total debt$18.03M$14.32M
Total liabilities$129.24M$84.33M
Shareholders' equity-$35.71M$30.15M
Net debt$12.22M$8.11M
Shares outstanding278,62744.00M
Cash flow statement
Operating cash flow-$41.42M-$31.90M
Capital expenditure$352,000$257,000
Free cash flow-$41.78M-$32.16M
Investing cash flow$23.23M$21.91M
Financing cash flow$17.91M-$4.78M
Depreciation & amortization$142,000$186,000
Stock-based compensation$5.11M$4.75M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.